Related Experiment Video
Updated: Sep 4, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study
Ailiana Santosa1, Stefan Franzén2,3, Jonatan Nåtman3
1School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. ailiana.santosa@gu.se.
Insights
Statin use in individuals aged 40 and over was associated with a reduced risk of COVID-19 hospitalization and death. This protective effect was observed across the general population and specific COVID-19 patient cohorts.
Area of Science:
- Epidemiology
- Pharmacology
Background:
- The relationship between statin use and COVID-19 outcomes is not fully understood.
- Statins are widely prescribed lipid-lowering medications with potential anti-inflammatory properties.
Purpose of the Study:
- To investigate the association between statin exposure and the risk and severity of COVID-19.
- To analyze these effects in the general population and in defined COVID-19 patient cohorts.
Main Methods:
- Utilized nationwide Swedish population-based register data, including the National Prescribed Drug Register and COVID-19 outcome registers.
- A cohort of individuals aged ≥40 years was selected, with statin exposure defined as prescriptions in the year prior to the index date.
- Cox regression with propensity score Average Treatment effect in the Treated (ATT) weighting was employed to control for confounding.
Main Results:
- Among 572,695 individuals, 22.3% were prior statin users.
- Statin users showed a reduced risk of hospitalization and COVID-19 death in the overall and onset cohorts after ATT weighting.
- In the hospitalized cohort, statin use was linked to lower mortality (HR=0.86) but not ICU admission.
Conclusions:
- Statin-treated individuals demonstrated lower COVID-19 mortality compared to non-users.
- Findings suggest a potential protective role of statins against severe COVID-19 outcomes, including death.
Abstract:
The impact of statins on COVID-19 remains unclear. This study aims to investigate whether statin exposure assessed both in the population and in well-defined cohorts of COVID-19 patients may affect the risk and severity of COVID-19 using nationwide Swedish population-based register data. A population ≥ 40 years was selected by age/sex-stratified random sampling from the Swedish population on 1 Jan 2020. COVID-19 outcomes were identified from the SmiNet database, the National Patient Register and/or Cause-of-Death Register and linked with the National Prescribed Drug Register and sociodemographic registers. Statin exposure was defined as any statin prescriptions in the year before index date. In Cox regressions, confounding was addressed using propensity score ATT (Average Treatment effect in the Treated) weighting. Of 572,695 individuals in the overall cohort, 22.3% had prior statin treatment. After ATT weighting, protective effects were observed among statin user for hospitalization and COVID-19 death in the overall cohort and onset cohort. In the hospitalized cohort, statin use was only associated with lower risk for death (HR = 0.86, 95% CI 0.79-0.95), but not ICU admission. Statin-treated individuals appear to have lower COVID-19 mortality than nonusers, whether assessed in the general population, from COVID-19 onset or from hospitalization.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Myocarditis III: Medical Management

